News

All dosing in the drisapersen clinical program had been placed on hold by GSK on September 20, 2013, upon announcement of the DEMAND III study results. The re-dosing

The Phase 3 clinical trial is designed to demonstrate the superiority, in terms of mortality at 28 days, of a plazomicin-based regimen compared with a colistin-based regimen in

The partnership establishes a major dystonia research prize to expand public awareness, acknowledge key scientific discoveries and incentivize the work of dedicated researchers in dystonia, an under-funded movement

The company will be developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which it will deploy at two leading medical institutions over the course of

MGB-BP-3 is the first antibacterial for over a decade with a novel mode of action from a truly novel class to be developed globally. Funding of £2.7m has

The deal will see Sanofi provide about $200m in equity investments, milestone payments and research and development services over the next four years. Sanofi has already paid MyoKardia

Tildrakizumab is a humanized, anti-IL-23p19 monoclonal antibody that binds specifically to IL-23p19 and is designed to selectively block the cytokine IL-23. It is currently being evaluated in Phase

SGX301 is a first-in-class, photodynamic therapy using safe visible light for activation and its active ingredient, synthetic hypericin, is a potent photosensitizer which is topically applied to skin

Trelagliptin succinate is a once-weekly dipeptidyl peptidase-IV (DPP-4) inhibitor that controls blood glucose levels by selectively and continually inhibiting DPP-4, which helps in increasing insulin secretion depending on